Restricted accessResearch articleFirst published online 2018-11
Effects of Herbal Formulas Bojungikgi-tang and Palmijihwang-hwan on Inflammation in RAW 264.7 Cells and the Activities of Drug-Metabolizing Enzymes in Human Hepatic Microsomes
In the present study, Bojungikgi-tang (BJIKT: Buzhongyiqi-tang, Hochuekki-to) and Palmijihwang-hwan (PMJHH: Baweidihuang-wan, Hachimijio-gan), traditional herbal formulas, investigated anti-inflammatory efficacies in murine macrophage cell line and the influence on the activities of drug-metabolizing enzymes (DMEs). The anti-inflammatory potentials of the herbal formulas were evaluated to inhibit the production of the inflammatory mediators and cytokines and the protein expression of inducible nitric oxide and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-treated RAW 264.7 cells. The activities of the major human DMEs, cytochrome P450 (CYP450) and UDP-glucuronosyltransferase (UGT) isozymes, were measured by in vitro enzyme assay systems. BJIKT and PMJHH significantly suppressed the prostaglandin E2 (PGE2) production (IC50 = 317.3 and 282.2 μg/mL, respectively) and the protein expression of COX-2 in LPS-treated RAW264.7 cells. On the human microsomal DMEs, BJIKT inhibited the activities of CYP1A2 (IC50 = 535.05 μg/mL), CYP2B6 (IC50 > 1000 μg/mL), CYP2C9 (IC50 = 800.78 μg/mL), CYP2C19 (IC50 = 563.11 μg/mL), CYP2D6 (IC50 > 1000 μg/mL), CYP2E1 (IC50 > 1000 μg/mL), CYP3A4 (IC50 = 879.60 μg/mL), UGT1A1 (IC50 > 1000 μg/mL), and UGT1A4 (IC50 > 1000 μg/mL), but it showed no inhibition of the UGT2B7 activity at doses less than 1000 μg/mL. PMJHH inhibited the CYP2D6 activity (IC50 = 280.89 μg/mL), but IC50 values of PMJHH exceeded 1000 μg/mL on the activities of CYP1A2, CYP2C19, CYP2E1, and CYP3A4. At concentrations less than 1000 μg/mL, PMJHH did not affect the activities of CYP2B6, CYP2C9, UGT1A1, UGT1A4, and UGT2B7. The results indicate that both BJIKT and PMJHH may be potential candidates to prevent and treat PGE2- and COX-2-mediated inflammatory diseases. In addition, this study will expand current knowledge about herb–drug interactions by BJIKT and PMJHH.
Get full access to this article
View all access options for this article.
References
1.
LarsenGL, HensonPM: Mediators of inflammation. Annu Rev Immunol, 1983; 1:335–359.
2.
SautebinL: Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy. Fitoterapia, 2000; 71Suppl 1: S48–S57.
3.
NathanC: Nitric oxide as a secretory product of mammalian cells. FASEB J, 1992; 6:3051–3064.
HartFD, HuskissonEC: Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use. Drugs, 1984; 27:232–255.
6.
SollAH, WeinsteinWM, KurataJ, McCarthyD: Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med, 1991; 114:307–319.
7.
PhilpJC, MaselliJ, PachterLM, CabanaMD: Complementary and alternative medicine use and adherence with pediatric asthma treatment. Pediatrics, 2012; 129:e1148–e1154.
8.
OngCK, BodekerG, GrundyC, BurfordG, SheinK: WHO Global Atlas of Traditional, Complementary and Alternative Medicine. World Health Organization, Center for Health Development, Kobe, Japan, 2005.
9.
LeeMY, ShinIS, JeonWY, et al.: Protective effect of Bojungikki-tang, a traditional herbal formula, against alcohol-induced gastric injury in rats. J Ethnopharmacol, 2012; 142:346–353.
10.
SeoCS, ShinHK: Quantitative analysis of twelve marker compounds in Palmijihwang-hwan using ultra-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Nat Prod Sci, 2014; 20:182–190.
11.
YangSH, YuCL: Antiinflammatory effects of Bu-zhong-yi-qi-tang in patients with perennial allergic rhinitis. J Ethnopharmacol, 2008; 115:104–109.
12.
SuzukiT, TakanoI, NagaiF, et al.: Suppressive effects of Hochu-ekki-to, a traditional Chinese medicine, on IgE production and histamine release in mice immunized with ovalbumin. Biol Pharm Bull, 1999; 22:1180–1184.
13.
IshimitsuR, NishimuraH, KawauchiH, KawakitaT, YoshikaiY: Dichotomous effect of a traditional Japanese medicine, bu-zhong-yi-qi-tang on allergic asthma in mice. Int Immunopharmacol, 2001; 1:857–865.
14.
YangSH, KaoTI, ChiangBL, ChenHY, ChenKH, ChenJL: Immune-modulatory effects of bu-zhong-yi-qi-tang in ovalbumin-induced murine model of allergic asthma. PLoS One, 2015; 10:e0127636.
15.
TajimaS, BandoM, YamasawaH, et al.: Preventive effect of Hochu-ekki-to on lipopolysaccharide-induced acute lung injury in BALB/c mice. Lung, 2006; 184:318–323.
16.
SassaS, SakamotoS, ZhouYF, MoriT, KikuchiT, ShinodaH: Preventive effects of a Chinese herbal medicine, hochu-ekki-to, on bone loss in ovariectomized rats. In Vivo, 2001; 15:25–28.
17.
SudoK, HondaK, TakiM, et al.: Effects of TJ-41 (Tsumura Hochu-ekki-to) on spermatogenic disorders in mice under current treatment with Adriamycin. Nihon Yakurigaku Zasshi, 1988; 92:251–261.
18.
WangXQ, TakahashiT, ZhuSJ, et al.: Effect of Hochu-ekki-to (TJ-41), a Japanese herbal medicine, on daily activity in a murine model of chronic fatigue syndrome. Evid Based Complement Alternat Med, 2004; 1:203–206.
19.
KimSH, LeeSE, OhH, et al.: The radioprotective effects of bu-zhong-yi-qi-tang: A prescription of traditional Chinese medicine. Am J Chin Med, 2002; 30:127–137.
20.
SakamotoS, KudoH, KawasakiT, KasaharaN, OkamotoR: Effect of ba-wei-di-huang-wan (hachimi-jio-gan) on thymidine kinase and its isozyme activities in the prostate glands in rats. Am J Chin Med, 1988; 16:29–36.
21.
UsukiS: Hachimijiogan produces testosterone in adult rat testes. Am J Chin Med, 1988; 16:93–105.
22.
KimHY, YokozawaT, ChoEJ, YamabeN: Protective effects of the Chinese prescription Hachimi-jio-gan against diabetic oxidative stress. J Pharm Pharmacol, 2004; 56:1299–1305.
23.
FuruyaY, KawakitaT, NomotoK: Immunomodulating effect of a traditional Japanese medicine, hachimi-jio-gan (ba-wei-di-huang-wan), on Th1 predominance in autoimmune MRL/MP-lpr/lpr mice. Int Immunopharmacol, 2001; 1:551–559.
24.
HirokawaS, NoseM, IshigeA, AmagayaS, OyamaT, OgiharaY: Effect of Hachimi-jio-gan on scopolamine-induced memory impairment and on acetylcholine content in rat brain. J Ethnopharmacol, 1996; 50:77–84.
25.
OkaH, GotoH, KoizumiK, et al.: Effect of Hachimijiogan against renal dysfunction and involvement of hypoxia-inducible factor-1α in the remnant kidney model. Evid Based Complement Alternat Med, 2011; 2011:348686.
26.
FirenzuoliF, GoriL: Herbal medicine today: Clinical and research issues. Evid Based Complement Alternat Med, 2007; 4Suppl 1:37–40.
27.
DeyD, ChaskarS, AthavaleN, ChitreD: Acute and chronic toxicity, cytochrome p450 enzyme inhibition, and HERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation. Biomed Res Int, 2015; 2015:971982.
28.
FooWY, TayHY, ChanEC, LauAJ: Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A. Biochem Pharmacol, 2015; 97:320–330.
29.
LiQ, WangL, DaiP, et al.: A combined strategy of mass fragmentation, post-column cobalt complexation and shift in ultraviolet absorption spectra to determine the uridine 5'-diphospho-glucuronosyltransferase metabolism profiling of flavones after oral administration of a flavone mixture in rats. J Chromatogr A, 2015; 1395:116–128.
30.
UrlacherVB, GirhardM: Cytochrome P450 monooxygenases: An update on perspectives for synthetic application. Trends Biotechnol, 2012; 30:26–36.
31.
KiserJJ, BurtonJRJr, EversonGT: Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol, 2013; 10:596–606.
32.
GargV, van HeeswijkR, LeeJE, AlvesK, NadkarniP, LuoX: Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology, 2011; 54:20–27.
33.
JinSE, KimOS, YooSR, et al.: Anti-inflammatory effect and action mechanisms of traditional herbal formula Gamisoyo-san in RAW 264.7 macrophages. BMC Complement Altern Med, 2016; 16:219.
34.
Life Technologies. Vivid CYP450 screening kits user guide: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/Vivid_CYP450_Screening_Kits_man.pdf (accessed November13, 2018).
35.
JinSE, SeoCS, ShinHK, HaH: Traditional herbal formulas to as treatments for musculoskeletal disorders: Their inhibitory effects on the activities of human microsomal cytochrome P450s and UDP-glucuronosyltransferases. Pharmacogn Mag, 2016; 12:241–252.
LeeYS, HanOK, ParkCW, et al.: Pro-inflammatory cytokine gene expression and nitric oxide regulation of aqueous extracted Astragali radix in RAW 264.7 macrophage cells. J Ethnopharmacol, 2005; 100:289–294.
38.
XieW, DuL: Diabetes is an inflammatory disease: Evidence from traditional Chinese medicines. Diabetes Obes Metab, 2011; 13:289–301.
39.
YaoCM, YangXW: Bioactivity-guided isolation of polyacetylenes with inhibitory activity against NO production in LPS-activated RAW264.7 macrophages from the rhizomes of Atractylodes macrocephala. J Ethnopharmacol, 2014; 151:791–799.
40.
YuGJ, ChoiIW, KimGY, et al.: Anti-inflammatory potential of saponins derived from cultured wild ginseng roots in lipopolysaccharide-stimulated RAW 264.7 macrophages. Int J Mol Med, 2015; 35:1690–1698.
41.
YangXL, LiuD, BianK, ZhangDD: Study on in vitro anti-inflammatory activity of total flavonoids from Glycyrrhizae Radix et Rhizoma and its ingredients. Zhongguo Zhong Yao Za Zhi, 2016; 38:99–104.
42.
ShinS, JeonJH, ParkD, et al.: Anti-inflammatory effects of an ethanol extract of Angelica gigas in a Carrageenan-air pouch inflammation model. Exp Anim, 2009; 58:431–436.
43.
KimKS, RheeHI, ParkEK, et al.: Anti-inflammatory effects of Radix Gentianae Macrophyllae (Qinjiao), Rhizoma Coptidis (Huanglian) and Citri Unshiu Pericarpium (Wenzhou migan) in animal models. Chin Med, 2008; 3:10.
44.
AshourML, WinkM: Genus Bupleurum: A review of its phytochemistry, pharmacology and modes of action. J Pharm Pharmacol, 2011; 63:305–321.
45.
KimSJ, KimMS: Inhibitory effects of cimicifugae rhizoma extracts on histamine, bradykinin and COX-2 mediated inflammatory actions. Phytother Res, 2000; 14:596–600.
46.
LiuCL, ChengL, KoCH, et al.: Bioassay-guided isolation of anti-inflammatory components from the root of Rehmannia glutinosa and its underlying mechanism via inhibition of iNOS pathway. J Ethnopharmacol, 2012; 143:867–875.
47.
SungYH, ChangHK, KimSE, et al.: Anti-inflammatory and analgesic effects of the aqueous extract of corni fructus in murine RAW 264.7 macrophage cells. J Med Food, 2009; 12:788–795.
48.
TianT, ChenH, ZhaoYY: Traditional uses, phytochemistry, pharmacology, toxicology and quality control of Alisma orientale (Sam.) Juzep: A review. J Ethnopharmacol, 2014; 158Pt A:373–387.
JeongJW, LeeHH, HanMH, et al.: Ethanol extract of Poria cocos reduces the production of inflammatory mediators by suppressing the NF-kappaB signaling pathway in lipopolysaccharide-stimulated RAW 264.7 macrophages. BMC Complement Altern Med, 2014; 14:101.
51.
HikinoH, KonnoC, TakataH, et al.: Antiinflammatory principles of Aconitum roots. J Pharmacobiodyn, 1980; 3:514–525.
52.
GalatiEM, MonforteMT, KirjavainenS, ForestieriAM, TrovatoA, TripodoMM: Biological effects of hesperidin, a citrus flavonoid. (Note I): Antiinflammatory and analgesic activity. Farmaco, 1994; 40:709–712.
53.
YuJY, HaJY, KimKM, JungYS, JungJC, OhS: Anti-inflammatory activities of licorice extract and its active compounds, glycyrrhizic acid, liquiritin and liquiritigenin, in BV2 cells and mice liver. Molecules, 2015; 20:13041–13054.
54.
FuY, ZhouE, WeiZ, et al.: Glycyrrhizin inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model. FEBS J, 2014; 281:2543–2557.
55.
RimHK, ChoW, SungSH, LeeKT: Nodakenin suppresses lipopolysaccharide-induced inflammatory responses in macrophage cells by inhibiting tumor necrosis factor receptor-associated factor 6 and nuclear factor-κB pathways and protects mice from lethal endotoxin shock. J Pharmacol Exp Ther, 2012; 342:654–664.
56.
ParkCH, YamabeN, NohJS, KangKS, TanakaT, YokozawaT: The beneficial effects of morroniside on the inflammatory response and lipid metabolism in the liver of db/db mice. Biol Pharm Bull, 2009; 32:1734–1740.
57.
LiY, LiZ, ShiL, et al.: Loganin inhibits the inflammatory response in mouse 3T3L1 adipocytes and mouse model. Int Immunopharmacol, 2016; 36:173–179.
58.
HancıD, AltunH, ÇetinkayaEA, MulukNB, CengizBP, CingiC: Cinnamaldehyde is an effective anti-inflammatory agent for treatment of allergic rhinitis in a rat model. Int J Pediatr Otorhinolaryngol, 2016; 84:81–87.
59.
KhanS, ShehzadO, ChengMS, LiRJ, KimYS: Pharmacological mechanism underlying anti-inflammatory properties of two structurally divergent coumarins through the inhibition of pro-inflammatory enzymes and cytokines. J Inflamm (Lond), 2015; 12:47.
60.
FlorentinoIF, SilvaDP, GaldinoPM, et al.: Antinociceptive and anti-inflammatory effects of Memora nodosa and allantoin in mice. J Ethnopharmacol, 2016; 186:298–304.
61.
AdewoyinM, MohsinSM, ArulselvanP, HusseinMZ, FakuraziS: Enhanced anti-inflammatory potential of cinnamate-zinc layered hydroxide in lipopolysaccharide-stimulated RAW 264.7 macrophages. Drug Des Devel Ther, 2015; 9:2475–2484.
62.
KimH, LiuKH: Screening for inhibitory effect on nine CYP isoforms by 20 herbal medications. J Life Sci, 2007; 17:334–339.
63.
LinJH, LuAY: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet, 1998; 35:361–390.
64.
GonzalezFJ, TukeyRH: Chapter 3: Drug metabolism. In: BruntonLL, LazoJS, ParkerKL. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th ed. McGraw Hill, New York, 2006, pp. 71–91.
65.
ShimadaT, YamazakiH, MimuraM, InuiY, GuengerichFP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther, 1994; 270:414–423.
66.
ZangerUM, SchwabM: Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 2013; 138:103–141.
67.
KimuraY, ItoH, HatanoT: Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol Pharm Bull, 2010; 33:1977–1982.
TukeyRH, StrassburgCP: Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol, 2000; 40:581–616.
70.
MackenziePI, OwensIS, BurchellB, et al.: The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 1997; 7:255–269.
71.
MinersJO, MackenziePI, KnightsKM: The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev, 2010; 42:196–208.
72.
KatohM, YoshiokaY, NakagawaN, YokoiT: Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. Drug Metab Pharmacokinet, 2009; 24:226–234.
73.
SonYH, KimHG, NamGS: Effect of Cnidii Rhizoma water extract on chemopreventive enzymes for hepatocarcinoma. Korean J Pharmacogn, 2003; 34:297–302.
74.
ParkJH, ParkJY, JuYS: Inhibitory effects of licorice ethanol extracts and glycyrrhizin on cytochrome P450 drug-metabolizing enzymes in human liver microsomes. Korean J Orient Prev Med Soc, 2003; 7:65–74.
75.
OrPM, LamFF, KwanYW, et al.: Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms. Phytomedicine, 2012; 19:535–544.
76.
HuangY, ZhengSL, XuZS, HouY: Effects of Alismatis rhizome on rat cytochrome P450 enzymes. Pharm Biol, 2014; 52:681–687.
77.
ParkHJ: Effects of herbal medicines including Cinnamomi Cortex on activity of several cytochrome P450 isoforms. Wonkwang University, Department Oriental Pharmacy (PhD Thesis), 2009.
78.
YeL, WangT, YangC, et al.: Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species. Toxicol Lett, 2011; 204:81–91.
ZhouSF, ZhouZW, YangLP, CaiJP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem, 2009; 16:3480–3675.
81.
Whirl-CarrilloM, McDonaghEM, HebertJM, et al.: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther, 2012; 92:414–417.
82.
LeeAJ, LeeHJ, KimJD, et al.: Changes of peripheral blood lymphocyte subtypes in patients with end stage cancer administered localized radiotherapy and Bojungikki-tang. Evid Based Complement Altern Med, 2014; 2014:207613.
83.
LeeSJ, ParkJB, KimD, et al.: In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions. Toxicol Lett, 2015; 232:458–465.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
